Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate Prostate01: Ifinatamab Deruxtecan vs Docetaxel in mCRPC
2024-517423-40-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS). Planned start Jun 2025; status: authorised.
02
Drugs
ifinatamab deruxtecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-517423-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517423-40-00.